GlassScriptPhysician profile
Theresa K Rourke
NPI 1912309162
$5,390.28
in general payments reported to CMS, 2019-2025
30 companies · $948 in 2025
The $948 reported for 2025 was more than what 84% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $794 · 2022: $866 · 2023: $1,570 · 2024: $1,211 · 2025: $948.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,730.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,729.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $700.07 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Merck Sharp & Dohme LLC | $495.31 | 2021-2025 | Verquvo |
| Boston Scientific Corporation | $434.14 | 2021-2024 | Watchman Access System, Watchman Flx |
| Esperion Therapeutics, INC. | $396.37 | 2021-2024 | Nexletol, Nexlizet |
| Novartis Pharmaceuticals Corporation | $360.35 | 2021-2025 | |
| Amgen INC. | $350.37 | 2021-2025 | Repatha, Repatha |
| Pfizer INC. | $269.97 | 2022-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $266.28 | 2021-2023 | Lifevest |
| Novo Nordisk INC | $234.13 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Impulse Dynamics (USA) INC. | $230.68 | 2022-2024 | Optimizer, Optimizer |
| Janssen Pharmaceuticals, INC | $220.69 | 2022-2024 | Xarelto |
| Alnylam Pharmaceuticals INC. | $147.22 | 2025 | Amvuttra, Onpattro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.75 | 2024 | Jardiance |
| United Therapeutics Corporation | $125.00 | 2021 | |
| Lilly USA, LLC | $120.83 | 2023 | Mounjaro |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $117.13 | 2025 | Descovy |
| E.R. Squibb & Sons, L.L.C. | $108.27 | 2021-2025 | Camzyos |
| Inspire Medical Systems, INC. | $107.25 | 2023-2024 | Inspire |
| Amarin Pharma, INC. | $99.88 | 2021-2023 | |
| Abbott Laboratories | $90.84 | 2022-2023 | Freestyle Libre 3 |
| Astellas Pharma US INC | $72.36 | 2021-2022 | |
| Coloplast Corp | $55.60 | 2024 | |
| Lexicon Pharmaceuticals, INC. | $50.88 | 2024 | |
| Sanofi-Aventis U.S. LLC | $38.54 | 2022-2023 | |
| Kiniksa Pharmaceuticals, LTD. | $37.32 | 2023 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $31.03 | 2021-2025 | |
| Edwards Lifesciences Corporation | $28.06 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Abiomed | $25.73 | 2023 | Impella |
| Bridgebio Pharma, INC. | $18.38 | 2025 | Attruby |
| Kowa Pharmaceuticals America, INC. | $11.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theresa Rourke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.